<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003388</url>
  </required_header>
  <id_info>
    <org_study_id>SC-8-ATG-9-03</org_study_id>
    <nct_id>NCT05003388</nct_id>
  </id_info>
  <brief_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS</brief_title>
  <official_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Foundation for Orthopaedics and Regenerative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Foundation for Orthopaedics and Regenerative Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic&#xD;
      adult umbilical cord derived mesenchymal stem cells for the treatment of multiple sclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) can be a devastating disease. There is evidence that mesenchymal stem&#xD;
      cell treatment is safe and efficacious for the treatment of MS. Patients with MS will receive&#xD;
      a single intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal&#xD;
      stem cells. The dose for the infusion will be 100 million cells. Patients will be evaluated&#xD;
      within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for&#xD;
      safety and efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>Clinical monitoring of possible adverse events or complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Kurtzke Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>EDSS is a scale to evaluate the function of the central nervous system. It will be completed for each follow up point</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of 100 million cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloRx</intervention_name>
    <description>cultured allogeneic adult umbilical cord derived mesenchymal stem cells</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Multiple Sclerosis&#xD;
&#xD;
          -  Understanding and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Chronic multisystem organ failure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Clinically significant abnormalities on pre-treatment laboratory evaluation&#xD;
&#xD;
          -  Medical condition that would (based on the opinion of the investigator) compromise&#xD;
             patient's safety.&#xD;
&#xD;
          -  Continued drug abuse&#xD;
&#xD;
          -  Pre-menopausal women not using contraception&#xD;
&#xD;
          -  Previous organ transplant&#xD;
&#xD;
          -  Hypersensitivity to sulfur&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadwick Prodromos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Foundation for Orthopaedics and Regenerative Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Surgical Associates Center</name>
      <address>
        <city>St. John's</city>
        <country>Antigua and Barbuda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadwick Prodromos, M.D.</last_name>
      <phone>8476996810</phone>
      <email>research@ismoc.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Antigua and Barbuda</country>
  </location_countries>
  <reference>
    <citation>Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014 Mar 25;14:58. doi: 10.1186/1471-2377-14-58. Review.</citation>
    <PMID>24666846</PMID>
  </reference>
  <reference>
    <citation>Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, Oertel FC, Scheel M, Hallimi M, Yaghmour N, Hur TB, Ginzberg A, Levy Y, Abramsky O, Karussis D. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020 Dec 1;143(12):3574-3588. doi: 10.1093/brain/awaa333.</citation>
    <PMID>33253391</PMID>
  </reference>
  <reference>
    <citation>Riordan NH, Morales I, Fern√°ndez G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz Rodriguez J. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018 Mar 9;16(1):57. doi: 10.1186/s12967-018-1433-7. Erratum in: J Transl Med. 2021 May 10;19(1):197.</citation>
    <PMID>29523171</PMID>
  </reference>
  <reference>
    <citation>Li JF, Zhang DJ, Geng T, Chen L, Huang H, Yin HL, Zhang YZ, Lou JY, Cao B, Wang YL. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23 Suppl 1:S113-22. doi: 10.3727/096368914X685005. Epub 2014 Nov 5.</citation>
    <PMID>25385295</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>stem cell treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

